These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
415 related articles for article (PubMed ID: 30452687)
41. A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer. Qin A; Rengan R; Lee S; Santana-Davila R; Goulart BHL; Martins R; Baik C; Kalemkerian GP; Hassan KA; Schneider BJ; Hayman JA; Jolly S; Hearn J; Lawrence TS; Towlerton AMH; Tewari M; Thomas D; Zhao L; Brown N; Frankel TL; Warren EH; Ramnath N Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):170-177. PubMed ID: 31756415 [TBL] [Abstract][Full Text] [Related]
42. Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. Lee JS; Lee KH; Cho EK; Kim DW; Kim SW; Kim JH; Cho BC; Kang JH; Han JY; Min YJ; Park K Lung Cancer; 2018 Aug; 122():234-242. PubMed ID: 30032838 [TBL] [Abstract][Full Text] [Related]
43. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. Nantavithya C; Gomez DR; Wei X; Komaki R; Liao Z; Lin SH; Jeter M; Nguyen QN; Li H; Zhang X; Poenisch F; Zhu XR; Balter PA; Feng L; Choi NC; Mohan R; Chang JY Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):558-563. PubMed ID: 29680255 [TBL] [Abstract][Full Text] [Related]
44. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ahmed KA; Stallworth DG; Kim Y; Johnstone PA; Harrison LB; Caudell JJ; Yu HH; Etame AB; Weber JS; Gibney GT Ann Oncol; 2016 Mar; 27(3):434-41. PubMed ID: 26712903 [TBL] [Abstract][Full Text] [Related]
45. Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals. Tournoy KG; Thomeer M; Germonpré P; Derijcke S; De Pauw R; Galdermans D; Govaert K; Govaerts E; Schildermans R; Declercq I; De Brucker N; Pat K; Van Herreweghe R; Van Zandweghe L; Vanmaele L; Van Damme V; Marien H; De Craene S; Fabry I; Alexander P; Vercauter P; Demedts I Lung Cancer; 2018 Jan; 115():49-55. PubMed ID: 29290261 [TBL] [Abstract][Full Text] [Related]
46. Successful continuous nivolumab therapy for metastatic non-small cell lung cancer after local treatment of oligometastatic lesions. Tobita S; Kinehara Y; Tamura Y; Kurebe H; Ninomiya R; Utsu Y; Kohmo S; Sato B; Nagai K; Maruoka S; Jokoji R; Koyama S; Tachibana I Thorac Cancer; 2020 Aug; 11(8):2357-2360. PubMed ID: 32567218 [TBL] [Abstract][Full Text] [Related]
47. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial. Krzakowski M; Provencio M; Utracka-Hutka B; Villa E; Codes M; Kuten A; Henke M; Lopez M; Bell D; Biti G; Merimsky O; Beorchia A; Riggi M; Caux NR; Pouget JC; Dubray B; David P J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302 [TBL] [Abstract][Full Text] [Related]
48. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity. Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225 [TBL] [Abstract][Full Text] [Related]
49. Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab? Chmielewska I; Dudzińska M; Szczyrek M; Świrska J; Wojas-Krawczyk K; Zwolak A PLoS One; 2021; 16(9):e0257484. PubMed ID: 34587185 [TBL] [Abstract][Full Text] [Related]
50. Effect of Tumor Location and Dosimetric Predictors for Chest Wall Toxicity in Single-Fraction Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. Manyam BV; Videtic GMM; Verdecchia K; Reddy CA; Woody NM; Stephans KL Pract Radiat Oncol; 2019 Mar; 9(2):e187-e195. PubMed ID: 30529796 [TBL] [Abstract][Full Text] [Related]
51. Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina. Martin C; Lupinacci L; Perazzo F; Bas C; Carranza O; Puparelli C; Kowalyszyn R; Magri I; Varela M; Richardet E; Vera K; Foglia S; Jerez I; Aman E; Martinengo G; Batagelj E; Dri A; Pilnik N; Roa GM; Mando P; Tsou F; Recondo G; Cayol F; Flores M; Sena S; Bagnes C; Waisberg FD; Minatta JN; Rizzo M Clin Lung Cancer; 2020 Sep; 21(5):e380-e387. PubMed ID: 32213298 [TBL] [Abstract][Full Text] [Related]
52. Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab. Minemura H; Moriya H; Imai H; Sugiyama T; Yamada Y; Higuchi M; Kaira K; Ozaki Y; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Suzuki H; Minato K; Shibata Y Thorac Cancer; 2020 Dec; 11(12):3521-3527. PubMed ID: 33044045 [TBL] [Abstract][Full Text] [Related]
53. Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. Hoffman PC; Cohen EE; Masters GA; Haraf DJ; Mauer AM; Rudin CM; Krauss SA; Huo D; Vokes EE Lung Cancer; 2002 Oct; 38(1):65-71. PubMed ID: 12367795 [TBL] [Abstract][Full Text] [Related]
54. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results. Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671 [TBL] [Abstract][Full Text] [Related]
55. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer. Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082 [TBL] [Abstract][Full Text] [Related]
56. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302 [TBL] [Abstract][Full Text] [Related]
57. Nivolumab-induced radiation recall pneumonitis in non-small-cell lung cancer patients with thoracic radiation therapy. Noda-Narita S; Naito T; Udagawa H; Goto K; Miyawaki T; Mamesaya N; Nakashima K; Kenmotsu H; Shimokawaji T; Kato T; Hakozaki T; Okuma Y; Nakamura M; Nakayama Y; Watanabe H; Kusumoto M; Ohe Y; Horinouchi H Cancer Sci; 2023 Feb; 114(2):630-639. PubMed ID: 36285515 [TBL] [Abstract][Full Text] [Related]
58. A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. Center B; Petty WJ; Ayala D; Hinson WH; Lovato J; Capellari J; Oaks T; Miller AA; Blackstock AW J Thorac Oncol; 2010 Jan; 5(1):69-74. PubMed ID: 20035186 [TBL] [Abstract][Full Text] [Related]
59. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients. Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S Oncology; 2016; 91(4):194-204. PubMed ID: 27427761 [TBL] [Abstract][Full Text] [Related]
60. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab. Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]